期刊文献+

伊班膦酸钠可防治肾小球疾病患者糖皮质激素引起的骨密度减低 被引量:5

Effect of sodium ibandronate injection on corticosteroid-induced reduced bone mineral density in the patients with glomerular disease
暂未订购
导出
摘要 目的 探讨伊班膦酸钠防治肾小球疾病患者糖皮质激素 (GC)所致的骨密度减低的疗效和安全性 ,观察期 1年。方法 前瞻性自身对照研究 16例骨量减少或骨质疏松患者 ,用强的松治疗半年后加用伊班膦酸钠 ,每 3个月 1mg ,每 3个月检测腰椎1~ 4(L1- 4)和股骨近端骨密度 (双能X线骨密度仪 )。结果 用GC治疗半年后各部位骨丢失 (13 .0~ 70 .8)mg/cm2 ,丢失率为 1 4 %~ 7 9%。加用伊班膦酸钠半年后L1 3 和股骨粗隆骨量增加 (5 . 2~ 2 6. 2 )mg/cm2 ,增加率为 1 0 %~ 3 6 % ;L4、股骨颈和三角区继续骨丢失 (0 . 5~ 6. 9)mg/cm2 ,丢失率 0 . 1%~ 0. 8%。 2 /16例出现能耐受的腰背部紧缩、酸沉和疼痛 ,4 8h内自行缓解。结论 间断静脉用伊班磷酸钠防治肾小球疾病患者GC所致的骨密度减低有效且副作用小 ,耐受性好。 Objective To investigate the efficacy and safety of ibandronate injections in treatment of corticosteroid-induced reduced bone mineral density(BMD) and osteoporosis in patients with glomerular disease. Methods In this prospective self control study, 16 patients with established osteoporosis and reduced BMD, after receiving prednison for half a year were freated with intravenoas used ibandronate (Ai-Ben),1mg 3-monthly and examined for BMD at the lumbar spines (L_1-L_4) and femoral neck by dual-energy X-ray absorptiometry every 3 months.Results After prednison therapy, the bone loss of every site was (13.0-70.8)mg/cm^2,the rate of bone loss being 1.4%-7.9%. After receiving ibandronate for half a year, the bone content of L_(1-3) and femoral trochanter increased (5.2-26.2)mg/cm^2,the increasing rate being 0.1%-0.8%,but the bone content of L_4,femoral neck and Ward's triangle continued losing (0.5-6.9)mg/cm^2,the rate of bone loss being 0.1%-0.8%. Two patients complained tolerable lumbodorsal straining pain, which remitted spontaneously within 48 hours.Conclusions Intermittent i.v. ibandronate injections are efficacious, well-tolerated, with rare side effect in treatmeut of corticosteroid-induced reduced BMD in patients with glomerular disease.
出处 《中国骨质疏松杂志》 CAS CSCD 2005年第1期88-90,共3页 Chinese Journal of Osteoporosis
关键词 伊班膦酸钠 患者 双能X线骨密度仪 肾小球疾病 治疗 糖皮质激素 GC 骨丢失 骨量减少 股骨粗隆 Ibandronate Glomerular disease Corticosteroid-induced osteoporosis Bone mineral density
  • 相关文献

参考文献10

  • 1Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum, 2001,44: 1496-1503.
  • 2傅淑霞,李绍梅,张丽萍,裴华颖,杨林,谭会斌,曾文.肾小球疾病与骨密度相关性研究[J].河北医科大学学报,2003,24(6):341-344. 被引量:7
  • 3Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone, 2001 ,29:498-505.
  • 4Sasaki N,Kusano E,Ando Y,et al. Glucocorticoid decreases circulating osteoprotegerin(OPG) :possible mechanism for glucocortioid induce osteoprpsis [ J]. Nephol Dial Transplant, 2001,16:479-482.
  • 5Israel E, Banrjee TR, Fitzmaurice GM, et al. Effects of inhaled glococorticoids on bone density in premenopausal women. N Engl J Med,2001,345:941-947.
  • 6傅淑霞,裴华颖,张建伟,李绍梅,张丽萍,扬林.糖皮质激素治疗对肾小球疾病患者骨密度的影响[J].中国医师杂志,2004,6(6):757-759. 被引量:2
  • 7Charvssieux PM, Arlot ME, Roux JP, et al. Effects of alendronate on bone qulity and remodling in glucocorticoid-induced ostoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res, 2000,15: 754-762.
  • 8Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol,2001,12:1530-1537.
  • 9Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int, 2003,14: 801-807.
  • 10Ringe JD, Dorst A, Faber H,et al. Three-monthly ibandronate bolus injection offers favourable tolerablility and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.Rheumatology, 2003,42:743-749.

二级参考文献20

  • 1Sasaki N, Kusano E, Ando Y, et al. Glucocorticoid decreases circulating osteoprotegerin (OPG) : possible mechanism for glucocortioid induce osteoporosis[J]. Nephol Dial Transplant,2001,16(3) :479-482.
  • 2Carbonare LD,Arlot ME, Chavassieux PM, et al. Compare of trabecular bone microarchitecture and remodling in glucocorticoid-induced and postmenopausal osteoporosis[J]. J Bone Miner Res, 2001,16 (1) : 97-103.
  • 3Martinez Diaz-Guerra G, Hawkins F, Rapado A, et al.Hormonal and anthrometric predictors of bone mass in healthy elderly men: major effect of sex hormone binding globulin, parathyroid hormone and bidy weight [ J ].Osteoporosis Int, 2001,12(3) : 178-184.
  • 4Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comoarison of vertical banded gastroplasty and medical intervention [J]. Obes Surg, 2003,13(3) :383-388.
  • 5Ilich JZ, Brownbill RA, Tamborini L. Bone and nutrition in elderly women: protein, energy, andcalcium main determinants of bone mineral density[J]. Eur J Clin Nutr,2003,57(4) :554-565.
  • 6Hegarty VM, May HM, Khaw KT. Tea drinking and bon emineral density in older women[J]. Am J Clin Nutr, 2000,71(4) : 1003-1007.
  • 7Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis[J].Arthritis Rheum,2001,44(7): 1496-1503
  • 8Mocharla H,Butch AW,Pappas AA,et al.Quantification of vitamin D receptor Mrna by ompetitive polymerase chain reaction in PBME:lake of correspondece with common allelic variants[J].J Bone Miner Res,1997,12(3):726-737
  • 9Yokoyama K,Shigematsu T,Tsukada T,et al.Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease[J].Kidney Int,1998,53(3):454-460
  • 10Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis[J]. Bone,2001,29(6): 498-505

共引文献6

同被引文献35

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部